Zhengye Biotechnology Operating Income Over Time

ZYBT Stock   0.90  0.07  7.22%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Zhengye Biotechnology Performance and Zhengye Biotechnology Correlation.
Operating Income is likely to gain to about 31.5 M in 2026.
Is there potential for Pharmaceuticals market expansion? Will Zhengye introduce new products? Factors like these will boost the valuation of Zhengye Biotechnology. Anticipated expansion of Zhengye directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Zhengye Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
(0.06)
Revenue Per Share
3.307
Quarterly Revenue Growth
(0.34)
Return On Assets
(0.03)
Zhengye Biotechnology's market price often diverges from its book value, the accounting figure shown on Zhengye's balance sheet. Smart investors calculate Zhengye Biotechnology's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Zhengye Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Zhengye Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zhengye Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zhengye Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Operating Income Analysis

Compare Zhengye Biotechnology and related stocks such as Incannex Healthcare, Cardiol Therapeutics, and Pro Dex Operating Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
20102011201220132014201520162017201820192020202120222023202420252026
IXHL(147 K)(3.4 M)(10 M)(6.3 M)(1.9 M)(577.2 K)(16.1 M)(2.4 M)(2 M)(2.8 M)(8.2 M)(10.2 M)(13.6 M)(45 M)(23.8 M)(21.4 M)(20.3 M)
CRDL(1.6 M)(1.6 M)(1.6 M)(1.6 M)(1.6 M)(1.6 M)(1.6 M)(1.6 M)(7.4 M)(10.9 M)(16.2 M)(30.6 M)(30.5 M)(22.5 M)(40.3 M)(36.2 M)(34.4 M)
PDEX(500 K)(1.4 M)(1.9 M)(814 K)(902 K)526 K2.7 M2.4 MM7.1 M5.1 M5.1 M5.8 M7.2 M10.7 M12.3 M12.9 M
SRZN(25.1 M)(25.1 M)(25.1 M)(25.1 M)(25.1 M)(25.1 M)(25.1 M)(25.1 M)(25.1 M)(25.1 M)(32.8 M)(54.4 M)(44.3 M)(45.8 M)(25.5 M)(23 M)(24.1 M)
SERA(16.6 M)(16.6 M)(16.6 M)(16.6 M)(16.6 M)(16.6 M)(16.6 M)(16.6 M)(16.6 M)(16.6 M)(18 M)(35.4 M)(45.7 M)(39.8 M)(36.6 M)(33 M)(34.6 M)
EXOZ(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.8 M)(5.9 M)(5.3 M)(5.1 M)
ATOS(122.9 K)(3.4 M)(5.1 M)(10.8 M)(12.2 M)(12.8 M)(7.2 M)(7.2 M)(11.4 M)(17.3 M)(14.6 M)(20.5 M)(27.7 M)(31.4 M)(27.6 M)(24.9 M)(23.6 M)
APYX(219.5 K)(18 K)M(3.7 M)(5.8 M)(7 M)(3.8 M)(5.3 M)(13.6 M)(20.9 M)(20.1 M)(14.4 M)(23.6 M)(17.3 M)(18.8 M)(17 M)(16.1 M)
TIL(6.6 M)(6.6 M)(6.6 M)(6.6 M)(6.6 M)(6.6 M)(6.6 M)(6.6 M)(6.6 M)(6.6 M)(33.6 M)(155.6 M)(206.2 M)(159.2 M)(73.5 M)(66.2 M)(69.5 M)
ONCY(577.4 K)(28.7 M)(36.7 M)(23.9 M)(18.8 M)(13.9 M)(15.3 M)(15.6 M)(16.7 M)(20.7 M)(19 M)(20.9 M)(20.7 M)(25 M)(35 M)(31.5 M)(29.9 M)

Zhengye Biotechnology and related stocks such as Incannex Healthcare, Cardiol Therapeutics, and Pro Dex Operating Income description

Operating Income is the amount of profit realized from Zhengye Biotechnology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Zhengye Biotechnology Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

My Equities

My Current Equities and Potential Positions

Zhengye Biotechnology Holding
ZYBT
ClassificationBiotech
Business AddressNo1 Lianmeng Road,
ExchangeNASDAQ Exchange
null 0.9

Additional Tools for Zhengye Stock Analysis

When running Zhengye Biotechnology's price analysis, check to measure Zhengye Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zhengye Biotechnology is operating at the current time. Most of Zhengye Biotechnology's value examination focuses on studying past and present price action to predict the probability of Zhengye Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zhengye Biotechnology's price. Additionally, you may evaluate how the addition of Zhengye Biotechnology to your portfolios can decrease your overall portfolio volatility.